

TABLE I . Studies of the Value of Resistance Testing in Creating Successful ART

GENOTYPING STUDIES			
STUDY	N	PRIMARY ENDPOINT	OUTCOME
GART	153	Change in viral RNA (at wk. 8)	Decline in viral RNA Group A: -1.12 log Group B: -0.52 log
VIRADAPT	108	Change in viral RNA(at wk. 24)	Decline in viral RNA Group A: -1.15 log Group B: -0.67 log
PHENOTYPING STUDIES			
VIRA 3001	221	Achieving VL <400 copies/mL (at wk. 16)	Observed Data: 59% of Group A had VL<400, 42% Group B had <400.
Melnick et al.	115	Decline in viral RNA (at wk. 4, 16)	At 4 wks, decline in viral RNA: Group A: -1.0 log Group B: -0.5 log (at wk. 16, no significant difference)
GENOTYPING, PHENOTYPING AND SOC STUDIES			
NARVAL	541	HIV RNA <200 (at wk. 24)	No significant difference

All studies compared regimens based on resistance testing (Group A) versus standard of care (Group B).